Rituximab biosimilar - Sandoz

Drug Profile

Rituximab biosimilar - Sandoz

Alternative Names: GP 2013; Rixathon; Riximyo

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sandoz
  • Developer Sandoz; University of Leeds
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Microscopic polyangiitis; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 09 Jan 2018 Chugai Pharmaceutical files patent infringement lawsuit and petition for provisional disposition order against Sandoz for Rituximab biosimilar
  • 03 Nov 2017 Adverse events data from a phase III trial in Rheumatoid arthritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 03 Nov 2017 Safety, efficacy, and immunogenicity data from the phase I/II ASSIST_RA trial in Rheumatoid arthritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top